Sonablate® continues to gain momentum as the preferred prostate tissue ablation device in the United States

CHARLOTTE, N.C., December 11, 2015 -- SonaCare Medical, LLC announces that Dr. Inderbir Gill performed two Sonablate® prostate tissue ablation procedures yesterday, December 10th, at Keck Medicine of USC. With the launch of University of Southern California's urologic HIFU program, Keck Medicine of USC becomes the first academic medical center in the United States to provide this pioneering technology since the FDA granted Sonablate® de novo clearance this past October for the ablation of prostate tissue.

Dr. Stephen Scionti launches his U.S.-based prostate HIFU program in Sarasota, Florida by performing two HIFU procedures on the same day.

CHARLOTTE, N.C., DECEMBER 08, 2015 -- SonaCare Medical, LLC reports that two Sonablate® HIFU procedures were performed on Friday, December 4th, by Dr. Stephen Scionti in Sarasota, Florida. Dr. Scionti is collaborating with Vituro Health to bring their HIFU treatment program to the Sarasota Interventional Radiology Center.  This facility becomes the third location, among six systems installed to date, to perform a Sonablate® HIFU prostate tissue ablation procedure in the United States since the device received regulatory authorization in October. Dr. Scionti and team have another procedure scheduled for today, and plan to have ten performed before December 25th.

UCLH recognized for their advancements in prostate cancer diagnosis and treatment methods.

CHARLOTTE, N.C., DECEMBER 01, 2015 -- SonaCare Medical congratulates the University College London Hospitals NHS Foundation Trust on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This prestigious award recognizes annually organizations that cultivate truly innovative methods of improving the patient care experience, and propose exciting enhancements to the medical landscape.

Michael J. Lazar, MD is the first physician to offer the recently FDA-cleared Sonablate® prostate tissue ablation procedure for men in San Francisco, CA.

CHARLOTTE, N.C., NOVEMBER 24, 2015 -- SonaCare Medical, LLC announces that a second location in the United States has performed a prostate tissue ablation procedure using the company's Sonablate® High Intensity Focused Ultrasound (HIFU) technology which FDA granted regulatory authorization for on October 9, 2015.

CHARLOTTE, N.C., OCTOBER  13, 2015 -- SonaCare Medical, LLC, a pioneer in minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance from the U.S. Food and Drug Administration (FDA) to market the Sonablate® 450  in the U.S. for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. SonaCare Medical expects to begin U.S. distribution this October.

HIFU company

Latest News

17 May 2018

SonaCare Medical congratulates Naren Sanghvi on his receipt of The William and Francis Fry Honorary Fellowship for Contributions to Therapeutic Ultrasound

10 April 2018

Over 120 urologists gather at Imperial College London to learn new diagnostic techniques and minimally invasive focal approaches for treating prostate cancer.